OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced that it has completed enrollment in its Oxabact ePHex phase III study.

Oxabact is an investigational bi-modal enteric biotherapy containing a lyophilized formulation of Oxalobacter formigenes for the treatment of adults and children with primary hyperoxaluria (PH) of all types. The objective of the study is to treat PH and prevent or delay kidney deterioration.

Learn more about OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria.